Moody National Bank Trust Division Sells 794 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Moody National Bank Trust Division cut its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) by 11.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,302 shares of the pharmaceutical company’s stock after selling 794 shares during the quarter. Moody National Bank Trust Division’s holdings in Vertex Pharmaceuticals were worth $1,644,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. BlackRock Inc. increased its stake in Vertex Pharmaceuticals by 1.7% in the fourth quarter. BlackRock Inc. now owns 23,944,931 shares of the pharmaceutical company’s stock worth $5,258,308,000 after purchasing an additional 397,036 shares during the period. State Street Corp increased its stake in Vertex Pharmaceuticals by 0.3% in the fourth quarter. State Street Corp now owns 12,356,915 shares of the pharmaceutical company’s stock worth $2,713,579,000 after purchasing an additional 33,499 shares during the period. Capital World Investors increased its stake in Vertex Pharmaceuticals by 4.3% in the fourth quarter. Capital World Investors now owns 11,520,855 shares of the pharmaceutical company’s stock worth $2,530,003,000 after purchasing an additional 478,553 shares during the period. Alliancebernstein L.P. increased its stake in Vertex Pharmaceuticals by 15.2% in the fourth quarter. Alliancebernstein L.P. now owns 10,443,771 shares of the pharmaceutical company’s stock worth $2,293,452,000 after purchasing an additional 1,374,923 shares during the period. Finally, Geode Capital Management LLC increased its stake in Vertex Pharmaceuticals by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 4,356,220 shares of the pharmaceutical company’s stock worth $954,276,000 after purchasing an additional 53,868 shares during the period. Institutional investors and hedge funds own 89.84% of the company’s stock.

Shares of VRTX stock opened at $272.31 on Thursday. Vertex Pharmaceuticals Incorporated has a 1-year low of $176.36 and a 1-year high of $292.75. The stock’s 50-day moving average is $264.63 and its 200 day moving average is $246.16. The company has a market cap of $69.64 billion, a P/E ratio of 28.66, a PEG ratio of 1.94 and a beta of 0.55. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.75 and a quick ratio of 4.60.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Rating) last issued its quarterly earnings data on Thursday, May 5th. The pharmaceutical company reported $3.16 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.01). Vertex Pharmaceuticals had a net margin of 30.84% and a return on equity of 32.24%. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.07 billion. Vertex Pharmaceuticals’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.54 EPS. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 12.47 EPS for the current year.

A number of analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $275.00 target price on shares of Vertex Pharmaceuticals in a research note on Wednesday, March 23rd. StockNews.com initiated coverage on Vertex Pharmaceuticals in a research note on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Piper Sandler cut their price target on Vertex Pharmaceuticals from $249.00 to $242.00 in a research note on Friday, May 6th. UBS Group raised their price target on Vertex Pharmaceuticals from $258.00 to $325.00 in a research note on Wednesday, April 13th. Finally, Argus raised their price target on Vertex Pharmaceuticals from $275.00 to $280.00 and gave the company a “buy” rating in a research note on Monday, June 13th. Seven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $282.61.

In other Vertex Pharmaceuticals news, EVP Bastiano Sanna sold 562 shares of the firm’s stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $267.71, for a total value of $150,453.02. Following the completion of the sale, the executive vice president now owns 43,343 shares of the company’s stock, valued at $11,603,354.53. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Kristen Ambrose sold 327 shares of the firm’s stock in a transaction dated Monday, April 25th. The stock was sold at an average price of $269.55, for a total value of $88,142.85. Following the completion of the sale, the chief accounting officer now directly owns 3,496 shares of the company’s stock, valued at approximately $942,346.80. The disclosure for this sale can be found here. In the last three months, insiders sold 36,683 shares of company stock valued at $10,227,645. Corporate insiders own 0.40% of the company’s stock.

Vertex Pharmaceuticals Profile (Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Featured Articles

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.